Skip to main content

The Use of Leukotriene Modifying Drugs in Asthma and Other Respiratory Diseases

Buy Article:

$55.00 plus tax (Refund Policy)

Only rarely in modern medicine is an entirely new class of drug developed. Recently, a number of drugs that act as leukotriene modifiers (LTM's) have been licensed for use in the treatment of asthma. Airway obstruction in asthma has two key components-bronchoconstriction of airway smooth muscle and airway inflammation. Although a number of mediators are involved in this process, it has been demonstrated that leukotrienes can precipitate both. Leukotrienes are formed in eosinophils, mast cells and neutrophils. LTM's have been shown to attenuate bronchial hyper-reactivity and reduce chemotaxis of inflammatory cells in the asthmatic airway. This article reviews the data from clinical trials of LTM's, discusses their role in asthma therapy and postulates on use in other common respiratory diseases.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Airway Inflammation; Asthma; Bronchoconstriction; Cystic Fibrosis; Leukotriene Modifying Drugs; Leukotrienes

Document Type: Review Article

Publication date: 2002-09-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more